Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference
26 nov. 2024 08h00 HE
|
Sagimet Biosciences Inc.
SAN MATEO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting...
Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024
18 nov. 2024 08h00 HE
|
Sagimet Biosciences Inc.
Subset analysis of FASCINATE-2 Phase 2 trial demonstrated denifanstat improved fibrosis in difficult-to-treat MASH patients Both artificial intelligence (AI) and conventional pathology demonstrated...
Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
14 nov. 2024 08h00 HE
|
Sagimet Biosciences Inc.
Denifanstat received Breakthrough Therapy designation from FDA for MASH Results from Phase 2b FASCINATE-2 study of denifanstat published in The Lancet Gastroenterology & Hepatology Successful...
Sagimet Biosciences to Participate in the UBS Global Healthcare Conference
07 nov. 2024 07h30 HE
|
Sagimet Biosciences Inc.
SAN MATEO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting...
Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024
29 oct. 2024 07h00 HE
|
Sagimet Biosciences Inc.
The planned registration program consists of two double-blind, placebo-controlled multicenter Phase 3 trials, FASCINATE-3 and FASCINIT, to evaluate the safety and efficacy of denifanstat in patients...
Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024
16 oct. 2024 07h00 HE
|
Sagimet Biosciences Inc.
SAN MATEO, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting...
Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology
11 oct. 2024 07h00 HE
|
Sagimet Biosciences Inc.
- Treatment with denifanstat achieved statistically significant and clinically meaningful improvements in disease activity, MASH resolution and fibrosis -- Results support advancement of denifanstat...
Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH
01 oct. 2024 07h00 HE
|
Sagimet Biosciences Inc.
Supported by positive data from Phase 2b FASCINATE-2 trial of denifanstat in patients with MASH Preparations are ongoing to initiate Phase 3 program for denifanstat by the end of 2024 SAN MATEO,...
Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 oct. 2024 00h05 HE
|
Sagimet Biosciences Inc.
SAN MATEO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN)...
Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit
12 sept. 2024 07h30 HE
|
Sagimet Biosciences Inc.
SAN MATEO, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN)...